Index -
P/E -
EPS (ttm) -2.12
Insider Own 2.95%
Shs Outstand 112.45M
Perf Week -2.07%
Market Cap 3.31B
Forward P/E -
EPS next Y -3.78
Insider Trans -12.49%
Shs Float 109.70M
Perf Month -7.42%
Enterprise Value 2.60B
PEG -
EPS next Q -0.90
Inst Own 64.67%
Short Float 22.91%
Perf Quarter -21.38%
Income -237.39M
P/S -
EPS this Y -169.52%
Inst Trans -3.44%
Short Ratio 8.00
Perf Half Y -22.67%
Sales 0.00M
P/B 4.62
EPS next Y -38.85%
ROA -28.31%
Short Interest 25.13M
Perf YTD -16.71%
Book/sh 6.34
P/C 4.63
EPS next 5Y -
ROE -29.23%
52W High 43.15 -32.10%
Perf Year -6.87%
Cash/sh 6.32
P/FCF -
EPS past 3/5Y -12.29% -23.00%
ROIC -33.28%
52W Low 18.92 54.86%
Perf 3Y 218.82%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y - -
Gross Margin -
Volatility 7.44% 6.50%
Perf 5Y 282.01%
Dividend TTM -
EV/Sales -
EPS Y/Y TTM -126.16%
Oper. Margin -
ATR (14) 1.94
Perf 10Y 1434.03%
Dividend Ex-Date -
Quick Ratio 28.34
Sales Y/Y TTM -
Profit Margin -
RSI (14) 42.64
Recom 1.11
Dividend Gr. 3/5Y - -
Current Ratio 28.34
EPS Q/Q -259.40%
SMA20 -5.72%
Beta 0.78
Target Price 93.39
Payout -
Debt/Eq 0.00
Sales Q/Q -
SMA50 -13.17%
Rel Volume 0.85
Prev Close 28.44
Employees 36
LT Debt/Eq 0.00
Earnings Feb 11 AMC
SMA200 -6.27%
Avg Volume 3.14M
Price 29.30
IPO Apr 29, 2015
Option/Short Yes / Yes
EPS/Sales Surpr. -14.15% -
Trades
Volume 2,666,919
Change 3.02%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-29-25 Initiated
Canaccord Genuity
Buy
$106
Apr-29-25 Initiated
Cantor Fitzgerald
Overweight
$104
Apr-08-25 Initiated
Goldman
Neutral
$30
Feb-13-25 Initiated
Scotiabank
Sector Outperform
$102
Feb-07-25 Initiated
Citigroup
Neutral
$38
Dec-02-24 Initiated
Piper Sandler
Overweight
Nov-22-24 Initiated
B. Riley Securities
Buy
$109
Nov-04-24 Reiterated
H.C. Wainwright
Buy
$90 → $102
Sep-11-24 Initiated
JP Morgan
Overweight
$80
Jun-27-24 Initiated
Morgan Stanley
Overweight
$105
May-16-24 Upgrade
Raymond James
Outperform → Strong Buy
$115 → $116
Mar-26-24 Reiterated
Oppenheimer
Outperform
$116 → $138
Mar-07-24 Initiated
Jefferies
Buy
$110
Feb-28-24 Reiterated
Oppenheimer
Outperform
$46 → $116
May-31-23 Resumed
ROTH MKM
Buy
$32
Mar-28-23 Reiterated
Maxim Group
Buy
$15 → $25
Mar-17-23 Initiated
Stifel
Buy
$22
Jul-29-21 Resumed
BTIG Research
Buy
$20
May-25-21 Downgrade
Raymond James
Strong Buy → Outperform
$27 → $12
Jun-05-20 Initiated
BMO Capital Markets
Outperform
$14
Show Previous Ratings
Feb-09-26 11:30AM
10:12AM
(Investor's Business Daily)
09:55AM
Feb-07-26 05:22PM
(Investor's Business Daily)
Feb-04-26 04:05PM
07:08PM
Loading…
Feb-03-26 07:08PM
Feb-02-26 11:00AM
Jan-30-26 05:45PM
10:06AM
08:47AM
Jan-28-26 09:09AM
Jan-27-26 01:35PM
09:41AM
Jan-26-26 11:35AM
09:15AM
03:14AM
Loading…
03:14AM
Jan-24-26 08:35PM
01:35PM
Jan-23-26 05:45PM
05:30AM
Jan-22-26 05:50PM
Jan-21-26 03:41PM
10:50AM
Jan-20-26 03:25PM
08:28AM
Jan-19-26 03:23PM
09:59AM
Jan-16-26 10:47AM
Jan-15-26 05:45PM
01:11PM
10:17AM
Loading…
10:17AM
05:10AM
Jan-14-26 01:25PM
Jan-13-26 09:58AM
09:06AM
Jan-12-26 07:00AM
Jan-09-26 05:45PM
09:58AM
07:12AM
Jan-08-26 08:38PM
09:30AM
07:00AM
Jan-07-26 07:00AM
Jan-06-26 09:41AM
Jan-05-26 05:50PM
04:03PM
10:37AM
08:34AM
Jan-02-26 09:01AM
Dec-31-25 09:15AM
08:07AM
Dec-30-25 05:45PM
Dec-29-25 02:34PM
Dec-24-25 10:49AM
Dec-23-25 05:45PM
04:01PM
(Investor's Business Daily)
10:46AM
09:30AM
08:58AM
Dec-22-25 06:46PM
(Investor's Business Daily)
06:50AM
Dec-18-25 01:13PM
12:35PM
09:53AM
Dec-16-25 01:35PM
10:50AM
Dec-15-25 11:11PM
05:45PM
10:32AM
Dec-13-25 04:30AM
Dec-12-25 11:17AM
10:37AM
Dec-11-25 04:28PM
(Investor's Business Daily)
08:10AM
(Investor's Business Daily)
07:44AM
07:35AM
Dec-10-25 10:17AM
07:43AM
07:10AM
Dec-09-25 09:27AM
Dec-04-25 12:21PM
(Investor's Business Daily) +8.92%
11:42AM
Dec-03-25 09:26AM
Dec-02-25 12:28PM
Dec-01-25 09:26AM
Nov-29-25 01:08PM
Nov-28-25 09:30AM
Nov-27-25 11:30AM
11:24AM
08:15AM
Nov-26-25 10:45AM
Nov-25-25 04:05PM
Nov-24-25 08:30AM
08:19AM
(Investor's Business Daily)
08:16AM
Nov-22-25 09:20AM
Nov-21-25 11:30AM
04:31AM
Nov-20-25 11:30AM
Nov-19-25 04:22PM
(Investor's Business Daily)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ZANTE GREG Chief Financial Officer Jan 05 '26 Sale 32.90 57,661 1,896,969 189,891 Jan 05 08:31 PM Mancini Marianna Chief Operating Officer Jan 05 '26 Sale 32.98 57,661 1,901,405 409,190 Jan 05 08:31 PM Lian Brian President & CEO Jan 05 '26 Sale 32.96 233,409 7,692,121 2,499,291 Jan 05 08:28 PM FOEHR MATTHEW W Director Jan 02 '26 Option Exercise 3.33 16,000 53,280 148,036 Jan 05 08:25 PM FOEHR MATTHEW W Director Jan 02 '26 Sale 35.11 16,000 561,694 132,036 Jan 05 08:25 PM MARIANNA MANCINI Officer Jan 05 '26 Proposed Sale 32.98 57,661 1,901,406 Jan 05 04:32 PM GREG ZANTE Officer Jan 05 '26 Proposed Sale 32.98 57,661 1,901,470 Jan 05 04:30 PM BRIAN LIAN Officer Jan 05 '26 Proposed Sale 32.96 233,409 7,692,134 Jan 05 04:29 PM MATTHEW W. FOEHR Director Jan 02 '26 Proposed Sale 35.11 16,000 561,694 Jan 02 04:46 PM Mancini Marianna Chief Operating Officer Oct 28 '25 Sale 35.00 6,185 216,492 382,467 Oct 28 07:51 PM Rowland Charles A Jr Director Oct 27 '25 Sale 35.57 60,000 2,134,278 30,000 Oct 28 07:49 PM Lian Brian President & CEO Oct 28 '25 Sale 35.01 38,989 1,364,923 2,419,109 Oct 28 07:48 PM ZANTE GREG Chief Financial Officer Oct 28 '25 Sale 35.00 6,185 216,481 173,592 Oct 28 07:47 PM GREG ZANTE Officer Oct 28 '25 Proposed Sale 35.01 6,185 216,531 Oct 28 04:34 PM MARIANNA MANCINI Officer Oct 28 '25 Proposed Sale 35.00 6,185 216,492 Oct 28 04:32 PM BRIAN LIAN Officer Oct 28 '25 Proposed Sale 35.01 38,989 1,364,923 Oct 28 04:27 PM CHARLES A ROWLAND JR. Director Oct 27 '25 Proposed Sale 35.57 60,000 2,134,278 Oct 27 04:25 PM Lian Brian President & CEO Jul 03 '25 Sale 27.80 26,889 747,633 2,388,014 Jul 03 03:31 PM ZANTE GREG Chief Financial Officer Jul 03 '25 Sale 27.76 4,266 118,428 168,660 Jul 03 03:31 PM Mancini Marianna Chief Operating Officer Jul 03 '25 Sale 27.77 4,266 118,473 377,535 Jul 03 03:30 PM GREG ZANTE Officer Jul 03 '25 Proposed Sale 27.76 4,266 118,428 Jul 03 01:07 PM MARIANNA MANCINI Officer Jul 03 '25 Proposed Sale 27.77 4,266 118,473 Jul 03 01:05 PM BRIAN LIAN Officer Jul 03 '25 Proposed Sale 27.80 26,889 747,633 Jul 03 01:01 PM FOEHR MATTHEW W Director Apr 11 '25 Option Exercise 8.00 20,786 166,288 132,036 Apr 14 07:26 PM Rouan Sarah Kathryn Director Mar 31 '25 Buy 24.15 1,240 29,943 1,240 Apr 02 06:29 PM